Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Canagliflozin | Low-Dose Naltrexone | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | — |
| Timing | — | — |
| Cycle Duration | — | — |
| Evidence Level | Moderate (longevity), Strong (cardiorenal) | Emerging |
SGLT2 inhibitor originally developed for type 2 diabetes. Blocks glucose reabsorption in kidneys, creating a mild glucose deficit that activates AMPK and mimics caloric restriction. Extended lifespan in male mice in the ITP.
Transient opioid receptor blockade that may increase endogenous endorphin signaling and modulate immune tone in off-label protocols.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →